STTK · XBRL financial data

Shattuck Labs financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STTK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	9,934	30,017	652	1,657	5,721	1,000
Research and development	37,483	56,563	82,899	74,310	67,211	35,273
General and administrative	9,382	18,723	21,082	19,304	19,077	17,235
Total operating expenses	46,865	75,286	103,981	93,614	86,288	52,508
Operating income (loss)	(36,931)	(45,269)	(103,329)	(91,957)	(80,567)	(51,508)
Interest income	549	625	1,592	4,669	5,174	2,703
Other income (expense)	(221)	(330)	(208)	(10)	(17)	(4)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(36,603)	(44,974)	(101,945)	(87,298)	(75,410)	(48,809)
Earnings per share, basic USD per share	(2.36)	(1.07)	(2.41)	(2.05)	(1.49)	(0.70)
Earnings per share, diluted USD per share	(2.36)	(1.07)	(2.41)	(2.05)	(1.49)	(0.70)
Weighted average shares, basic thousands of shares	15,506	42,032	42,379	42,600	50,758	69,585
Weighted average shares, diluted thousands of shares	15,506	42,032	42,379	42,600	50,758	69,585

Fiscal years (STTK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	157,898	92,268	47,379	125,626	57,387	54,192
Marketable securities	177,551	176,536	113,901	4,999	—	—
Prepaid and other current assets	10,190	19,462	23,304	12,595	6,228	4,410
Total current assets	345,639	288,266	184,584	143,220	79,215	82,475
Property and equipment, net	3,000	9,938	17,671	13,804	9,812	6,114
Right-of-use asset	—	—	2,635	2,271	1,843	1,337
Total assets	348,988	298,585	205,324	159,564	91,049	91,026
Accounts payable	1,754	10,012	7,170	1,587	2,419	2,101
Total current liabilities	16,834	24,586	24,965	11,453	8,917	7,052
Lease liability, non-current	—	0	4,202	3,406	2,506	1,584
Total liabilities	39,127	26,799	29,167	14,859	11,423	8,636
Accumulated deficit	(72,093)	(117,067)	(219,012)	(306,310)	(381,720)	(430,529)
Total stockholders' equity	309,861	271,786	176,157	144,705	79,626	82,390
Total liabilities and equity	348,988	298,585	205,324	159,564	91,049	91,026
Common shares outstanding (cover page) thousands of shares	41,776	42,364	42,449	47,475	47,899	71,564

Fiscal years (STTK's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(36,603)	(44,974)	(101,945)	(87,298)	(75,410)	(48,809)
Stock-based compensation	1,266	5,467	6,462	6,939	9,546	6,995
Depreciation and amortization	600	1,400	3,100	4,000	3,800	3,700
Net cash from operating activities	(33,659)	(57,116)	(94,498)	(81,228)	(60,515)	(39,882)
Purchases of property and equipment	727	7,926	11,614	407	59	71
Net cash from investing activities	(146,322)	(10,443)	49,438	110,859	(8,511)	(7,887)
Proceeds from issuing common stock	—	—	0	48,170	—	44,475
Net cash from financing activities	330,866	1,929	171	48,616	787	44,574
Net change in cash	150,885	(65,630)	(44,889)	78,247	(68,239)	(3,195)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Shattuck Labs	61,758	0	(17,470)*	101.8M	14.3 quarters	Q3 FY26 10-QSep 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.